OBJECTIVE: The postoperative development or exacerbation of interstitial pneumonia (IP) in lung cancer patients often affects prognoses. We analyzed the patients who suffered from IP after surgery, to determine treatment and prevention of IP. METHODS: One hundred and one consecutive patients who underwent resection were enrolled in the study. Clinical background and post-, perioperative course were compared between patients who developed IP and those who did not. RESULTS: If IP developed or was exacerbated, steroid pulse (SP) therapy, immunosuppressant (IS) therapy or nitric oxide (NO) inhalation therapy was employed. Of 101 patients, 20 had suffered from IP before surgery. In four of these 20 (20%), postoperative exacerbation was observed. SP therapy was given to all patients. To one patient, IS and NO therapy were added. Three of the four patients died. 81 patients did not have IP; three of them (3.7%) developed IP after the operation and were treated with SP therapy. To one patient, IS and NO therapy were added. Two of the three patients died. IP development or exacerbation after surgery was observed in seven of 101 patients, and five of them died. It was significantly more frequent in patients with poorly differentiated squamous cell carcinoma, restrictive change in pulmonary function tests, and a low percentage diffusion capacity for carbon monoxide. Postoperative development or exacerbation was observed in patients who had undergone lobectomy or pneumonectomy. CONCLUSIONS: Postoperative IP is a serious complication. Further studies are needed to determine definitive therapeutic options. For the patients with the aforementioned risk factors, limited surgery must be considered.
OBJECTIVE: The postoperative development or exacerbation of interstitial pneumonia (IP) in lung cancer patients often affects prognoses. We analyzed the patients who suffered from IP after surgery, to determine treatment and prevention of IP. METHODS: One hundred and one consecutive patients who underwent resection were enrolled in the study. Clinical background and post-, perioperative course were compared between patients who developed IP and those who did not. RESULTS: If IP developed or was exacerbated, steroid pulse (SP) therapy, immunosuppressant (IS) therapy or nitric oxide (NO) inhalation therapy was employed. Of 101 patients, 20 had suffered from IP before surgery. In four of these 20 (20%), postoperative exacerbation was observed. SP therapy was given to all patients. To one patient, IS and NO therapy were added. Three of the four patients died. 81 patients did not have IP; three of them (3.7%) developed IP after the operation and were treated with SP therapy. To one patient, IS and NO therapy were added. Two of the three patients died. IP development or exacerbation after surgery was observed in seven of 101 patients, and five of them died. It was significantly more frequent in patients with poorly differentiated squamous cell carcinoma, restrictive change in pulmonary function tests, and a low percentage diffusion capacity for carbon monoxide. Postoperative development or exacerbation was observed in patients who had undergone lobectomy or pneumonectomy. CONCLUSIONS: Postoperative IP is a serious complication. Further studies are needed to determine definitive therapeutic options. For the patients with the aforementioned risk factors, limited surgery must be considered.
Authors: R M Cherniack; T V Colby; A Flint; W M Thurlbeck; J A Waldron; L Ackerson; M I Schwarz; T E King Journal: Am J Respir Crit Care Med Date: 1995-04 Impact factor: 21.405
Authors: R J Ginsberg; L D Hill; R T Eagan; P Thomas; C F Mountain; J Deslauriers; W A Fry; R O Butz; M Goldberg; P F Waters Journal: J Thorac Cardiovasc Surg Date: 1983-11 Impact factor: 5.209
Authors: K Yoshimura; T Nakatani; Y Nakamori; N Chonabayashi; A Tachibana; K Nakata; H Okano; H Tanimoto Journal: Nihon Kyobu Shikkan Gakkai Zasshi Date: 1984-11
Authors: S Hojo; J Fujita; I Yamadori; T Kamei; T Yoshinouchi; Y Ohtsuki; H Okada; S Bandoh; Y Yamaji; J Takahara; T Fukui; M Kinoshita Journal: Eur Respir J Date: 1998-12 Impact factor: 16.671
Authors: Maya M Juarez; Andrew L Chan; Andrew G Norris; Brian M Morrissey; Timothy E Albertson Journal: J Thorac Dis Date: 2015-03 Impact factor: 2.895